FPC
AGRX

Falcon Point Capital’s Agile Therapeutics AGRX Stock Holding History

Falcon Point Capital’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-14
Closed -$71K – 129
2018
Q1 		$71K Sell
14
-18
-56% -$119K 0.01% 114
2017
Q4 		$171K Sell
32
-14
-30% -$130K 0.03% 116
2017
Q3 		$432K Buy
+46
New +$353K 0.06% 99

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Falcon Point Capital's AGRX Position: Q2 2018 in Review

Falcon Point Capital sold out of Agile Therapeutics (AGRX) in Q2 2018, closing a stake of 14 shares — an estimated $71K sold.

Falcon Point Capital first reported a position in AGRX in Q3 2017 and held it in 3 quarters. The position peaked at $432K in Q3 2017. 38 funds tracked by Wall St. Rank hold AGRX as of Q2 2018.

  • Falcon Point Capital reported no remaining Agile Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Falcon Point Capital sold 14 Agile Therapeutics shares in Q2 2018, an estimated $71K.
  • Falcon Point Capital first reported a position in Agile Therapeutics in Q3 2017 and held it in 3 quarters.
  • Falcon Point Capital's Agile Therapeutics position peaked at $432K in Q3 2017.
  • 38 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2018.

Based on Falcon Point Capital's 13F filing for Q2 2018, filed 7 Aug 2018.